AKRO (Akero Therapeutics, Inc.) Earnings per share for the last four quarters

Akero Therapeutics Inc (AKRO) - corporate logo

The operating environment for Akero Therapeutics (AKRO) remains stable and shielded from geopolitical risks. The year-over-year EPS trend (trailing 12 months) demonstrates that the parameter value is -0.10. While the business is not subject to economic cycles, it remains dependent on MASH clinical trial outcomes. The EFX drug and prospects for FDA approval are the primary growth drivers.

AKRO akerotx.com Net earnings per share (EPS TTM) (02/11/2024 - 12/20/2025)

AKRO (Akero Therapeutics): analytical breakdowns and indicator data

- business market valuation indicators:
Fundamental company valuation:AKRO (Akero Therapeutics, Inc.)
Core merchandise of Akero Corp

To protect capital from market volatility, it is essential for investors to track the dynamics of earnings per share, which in this case reflects the efficiency of implementing robotic laboratories and predictive data analysis systems at Akero Therapeutics (AKRO). By analyzing the 12-month YoY EPS trend, you assess the annual growth of net income per share over a rolling period, allowing you to identify fundamental business growth regardless of quarterly fluctuations.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Inc|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (Crinetics Pharmaceuticals, Inc.)|Earnings per share for the last twelve months newamsterdampharma.com NAMS|Soleno Therapeutics Corp (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS